[{"id":"fa5846d1-0a7a-44da-91ce-c0f902f44674","acronym":"","url":"https://clinicaltrials.gov/study/NCT03708211","created_at":"2021-01-18T18:10:52.137Z","updated_at":"2024-07-02T16:36:36.774Z","phase":"Phase 1","brief_title":"A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT03708211","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simurosertib (TAK-931)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 12/03/2019","primary_completion_date":" 12/03/2019","study_txt":" Completion: 12/03/2019","study_completion_date":" 12/03/2019","last_update_posted":"2020-12-29"}]